EU politicos press for April regulation on clinical data disclosure
This article was originally published in Scrip
Executive Summary
The continuing currency and economic crisis in Europe, spiced this week by the panic in Cyprus’s banking system, has not deflected European politicians from the much more urgent business of trying to loosen pharma’s hold on clinical data. In the European Parliament, MEPs backed calls for trial data to be published when a new drug has been approved for marketing. While most of the vocal members favored data publication, opinions differed as to how much data should be released, at what point and in what manner.
You may also be interested in...
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.